Surveillance of autoimmune conditions following routine use of quadrivalent human papillomavirus vaccine - Concepedia

Concepedia

Publication | Open Access

Surveillance of autoimmune conditions following routine use of quadrivalent human papillomavirus vaccine

DOI Full Paper Access

197

Citations

11

References

2011

Year

Chun Chao, Nicola P. Klein, Christine Velicer, Lina S. Sy, Jeff Slezak, Harpreet S. Takhar, Bradley K. Ackerson, T. Craig Cheetham, John Hansen, Kamala Deosaransingh,

Journal of Internal Medicine

Abstract

No autoimmune safety signal was found in women vaccinated with HPV4.

References

	Year	Citations
Quadrivalent Vaccine against Human Papillomavirus to Prevent High-Grade Cervical Lesions New England Journal of Medicine	2007	2K
Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP) Lauri E. Markowitz, Eileen F. Dunne, Mona Saraiya, PsycEXTRA Dataset GynecologyAdvisory CommitteeVaccine HesitancyCarcinomaCervical Cancer Prevention	2007	1.9K
Quadrivalent Vaccine against Human Papillomavirus to Prevent Anogenital Diseases Suzanne M. Garland, Mauricio Hernández‐Ávila, Cosette M. Wheeler, New England Journal of Medicine	2007	1.9K
Centers for Disease Control and Prevention (CDC) : Advisory Committee on Immunization Practices (ACIP) : Quadrivalent human papillomavirus vaccine : recommendations of the Advisory Committee on Immunization Practices (ACIP) Markowitz Le Medical Entomology and Zoology VaccinationImmunization PracticesPreventive MedicineCervical CancerHealth Policy	2007	1.6K
Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial Luisa L. Villa, Ronaldo Lúcio Rangel Costa, Carlos Alberto Petta, The Lancet Oncology VaccinationVaccinologyVaccine DevelopmentCervical CancerHuman Papillomavirus Vaccines	2005	1.6K
High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up Luisa L. Villa, Ronaldo Lúcio Rangel Costa, Carlos Alberto Petta, British Journal of Cancer	2006	804
Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials Kevin A. Ault The Lancet VaccinationVaccine SafetyCervical Intraepithelial NeoplasiaCervical Cancer ScreeningCancer-associated Virus	2007	586
The vaccine adverse event reporting system (VAERS) Robert T. Chen, John R. Mullen, Scott W. Hayes, Vaccine VaccinationVaccine SafetyVaccinologyPreventive MedicineVaccine Surveillance	1994	487
Postlicensure Safety Surveillance for Quadrivalent Human Papillomavirus Recombinant Vaccine Barbara A. Slade JAMA	2009	467
The Vaccine Adverse Event Reporting System (VAERS) Vaccine VaccinationVaccine SafetyVaccinologyPreventive MedicineVaccine Surveillance	1994	394

Page 1